Back to Search Start Over

Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.

Authors :
Kazuo Tamura
Hiroo Katsuya
Kenji Ishitsuka
Tatsuro Jo
Kunihiro Tsukasaki
Yukiyoshi Moriuchi
Eisaburo Sueoka
Shinichiro Yoshida
Hitoshi Suzushima
Masaharu Miyahara
Kiyoshi Yamashita
Tetsuya Eto
Junji Suzumiya
Mototsugu Shimokawa
Kazuhiro Kawai
Masahiro Amano
Atae Utsunomiya
Ryosuke Hino
Shuichi Hanada
Source :
Blood. 7/6/2017, Vol. 130 Issue 1, p39-47. 9p. 3 Charts, 2 Graphs.
Publication Year :
2017

Abstract

Adult T-cell leukemia-lymphoma (ATL) has been divided into 4 clinical subtypes: acute, lymphoma, chronic, and smoldering. The aim of this study is to develop a novel prognostic index (PI) for chronic and smoldering ATL. We conducted a nationwide retrospective survey on ATL patients, and 248 fully eligible individuals were used in this analysis. In the univariate analysis, sex, performance status, log10 (soluble interleukin-2 receptor [sIL-2R]), neutrophils count, and lymphadenopathy showed values of P < .05 in training samples. A multivariate analysis was performed on these factors, and only log10 (sIL-2R) was identified as an independent prognostic factor in training samples. Using a regression coefficient of this variable, a prognostic model was formulated to identify different levels of risk: indolent ATL-PI (iATL-PI) = 1.51 × log10 (sIL-2R [U/mL]). The values calculated by iATL-PI were divided into 3 groups using a quartile point. In the validation sample, median survival times (MSTs) were 1.6 years, 5.5 years, and not reached for patients in the high-, intermediate-, and low-risk groups, respectively (P < .0001). To make the scoring system clinically practicable, we simplified iATL-PI according to trichotomizing sIL-2R at 1000 and 6000 U/mL, using a quartile point. Patients with more than 6000 U/mL sIL-2R were categorized into the high-risk group, less than and equal to 1000 U/mL into the low-risk group, and the others into the intermediate-risk group, and MSTs were 1.6 years, not reached, and 5.5 years, respectively (P < .0001). iATL-PI has potential as a novel tool for a risk-adapted therapeutic approach. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00064971
Volume :
130
Issue :
1
Database :
Academic Search Index
Journal :
Blood
Publication Type :
Academic Journal
Accession number :
123971481
Full Text :
https://doi.org/10.1182/blood-2017-01-757542